Palisade Bio (PALI) Retained Earnings (2010 - 2026)
Palisade Bio (PALI) posted quarterly Retained Earnings of $288.0 million for Q1 2026, up 308.44% year-over-year from $70.5 million in Q1 2025, and up 2.67% quarter-over-quarter from $280.5 million in Q4 2025.
Palisade Bio (PALI) Retained Earnings (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Retained Earnings for 17 consecutive years, with $288.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 308.44% year-over-year to $288.0 million; the TTM figure through Mar 2026 stood at $288.0 million (up 308.44% YoY), while the FY2025 annual figure was $280.5 million, up 95.6% from the prior year.
- Retained Earnings improved to $288.0 million in Q1 2026 per PALI's latest filing, from $280.5 million in the prior quarter.
- Across five years, Retained Earnings topped out at $288.0 million in Q1 2026 and bottomed at -$143.8 million in Q3 2025.
- Historically, Retained Earnings has averaged $26.5 million across 5 years, with a median of $105.2 million in 2022.
- Annual changes were most pronounced in 2022 — Retained Earnings sank 3560670.89% — and 2026, when it jumped 308.44%.
- Palisade Bio's Retained Earnings stood at -$109.2 million in 2022, then slipped by 11.28% to -$121.5 million in 2023, then surged by 218.02% to $143.4 million in 2024, then soared by 95.6% to $280.5 million in 2025, then climbed by 2.67% to $288.0 million in 2026.
- Business Quant data shows PALI's Retained Earnings at $288.0 million in Q1 2026, $280.5 million in Q4 2025, and -$143.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - | 292.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 292.91 Mn |
| Mar 31, 2026 | 288.01 Mn |
| Dec 31, 2025 | 280.51 Mn |
| Sep 30, 2025 | -143.83 Mn |
| Jun 30, 2025 | -140.96 Mn |
| Mar 31, 2025 | -138.17 Mn |
| Dec 31, 2024 | 143.41 Mn |
| Sep 30, 2024 | -132.60 Mn |
| Jun 30, 2024 | 139.05 Mn |
| Mar 31, 2024 | -125.03 Mn |
| Dec 31, 2023 | -121.51 Mn |
| Sep 30, 2023 | 132.52 Mn |
| Jun 30, 2023 | 130.65 Mn |
| Mar 31, 2023 | 125.23 Mn |
| Dec 31, 2022 | -109.19 Mn |
| Sep 30, 2022 | 116.84 Mn |
| Jun 30, 2022 | 105.18 Mn |
| Mar 31, 2022 | -98.85 Mn |
| Dec 31, 2021 | 102.00 Mn |
| Sep 30, 2021 | 99.50 Mn |